This is the program for the 2010 Joint Statistical Meetings in Vancouver, British Columbia.
Activity Details
583 * | Wed, 8/4/2010, 2:00 PM - 3:50 PM | CC-117 (West) |
Statistical Strategies for Oncology Trials — Contributed Papers | ||
Biopharmaceutical Section | ||
Chair(s): Aloka Chakravarty, FDA | ||
2:05 PM | Bias in Oncology Time-to-Event Data Analysis — Din Chen, Georgia Southern University ; Yuhlong Lio, The University of South Dakota ; Yibin Wang, Novartis | |
2:35 PM | Exponential Failure-Time Mixture Model for Evaluating Efficacy in the Presence of a Biomarker: KRAS Validation — Kallappa M. Koti, FDA | |
2:50 PM | Case Study: Benefits of an Adaptive Clinical Trial Design in Oncology — Darcy Hille, Merck & Co., Inc. ; Christine K. Gause, Merck Research Laboratories ; Jason B. Clark, Merck Research Laboratories ; Sarah Hoagey, Merck & Co., Inc. ; Keaven M. Anderson, Merck Research Laboratories | |
3:05 PM | Drug Regimen Selection in Early-Stage Two-Arm Oncology Clinical Trials — Guohui Liu, Millennium Pharmaceuticals, Inc. ; Xuedong Chi, Millennium Pharmaceuticals, Inc. | |
3:20 PM | Statistical Methods for a Phase II Oncology Trial with a GMI Endpoint — Stephanie Ann Kovalchik, University of California, Los Angeles ; William Leonard Mietlowski, Novartis Oncology | |
3:35 PM | Sensitivity Analysis for PFS — Alicia Zhang, Amgen Inc. ; Alan Rong, Amgen Inc. ; Ying Tian, Amgen Inc. ; Michael Wolf, Amgen Inc. |
2010 JSM Online Program Home
For information, contact jsm@amstat.org or phone (888) 231-3473.
If you have questions about the Continuing Education program, please contact the Education Department.